Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

RTTNews | 373 hari yang lalu
Stocktwits
Ginkgo Bioworks Expects To Meet FY23 Revenue Guidance Ranges

(RTTNews) - Ahead of its presentation at the 42nd Annual J.P. Morgan Healthcare Conference later on Wednesday, Ginkgo Bioworks (DNA) said it expects to meet its previously disclosed new program and revenue guidance ranges in 2023, based on its preliminary unaudited estimates.

Fiscal 2023, the company continues to expect total revenue between $250 million and $260 million, with Cell Engineering revenue between $145 million and $150 million as well as Biosecurity revenue up to $110 million.

The company added that New Cell Programs are expected to be within the previously disclosed guidance range of 80 to 85 new Cell Programs added to the platform in 2023.

A business review, including a discussion of Ginkgo's platform services for large scale data generation and AI to enable biopharma R&D, will be featured in a presentation.

Teg: DNA
Stocktwits
read more
Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks Acquires Microbial Innovation Firm AgBiome's Platform Assets

Ginkgo Bioworks (DNA), which is building the leading platform for cell programming and biosecurity, announced Thursday the acquisition of microbial innovation firm AgBiome, Inc.'s platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline.
RTTNews | 281 hari yang lalu
Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Ginkgo Bioworks To Acquire Zymergen In All-stock Deal

Cell programming firm Ginkgo Bioworks Holdings, Inc. (DNA) and biotechnology company Zymergen, Inc. (ZY) announced Monday they have entered into a definitive agreement under which Ginkgo will acquire Zymergen in an all-stock transaction that values Zymergen at an approximately $300 million market capitalization.
RTTNews | 907 hari yang lalu
Alat
Kalendar Ekonomi
Market Hours
Interest Rates
Holidays Calendar
Pasaran Forex
Volatiliti Forex
Korelasi Forex
Berita Forex
forex analysis
Data COT
Kecairan
Kalkulator Forex
Peta Panas Forex
Indicators Heatmap
Komuniti
Komuniti
Sistem
Sistem Paling Popular
Strategi
Peraduan
Carta Forex
Sentimen Forex
Petunjuk Outlook
Ulasan
Broker
Prop Trading Firms
Perkhidmatan VPS
Penyedia Isyarat
Perkhidmatan Pengaturcaraan EA
Affiliate Programs
Perkhidmatan PAMM Broker
Perkhidmatan Program Rebat
Platform Dagangan
Penasihat Pakar
Pertukaran Kripto
Trading Courses
Broker
Spread Forex
Sebut Harga Forex Broker
Pertukaran Broker Forex
Jumlah Broker Forex
Promosi Broker Forex Broker News
Platform
Widget
Ciri-ciri
API
RSS
Stock Portfolio
Affiliate Software
Carta Lanjutan
Sokongan
Soalan Lazim
Bantuan
Hubungi Kami
Laporkan pepijat!
Mengenai
Blog
&salin; 2025 Myfxbook Ltd. Hak Cipta Terpelihara.
PERINGATAN RISIKO TINGGI: Perdagangan pertukaran mata wang asing mempunyai risiko tinggi yang mungkin tidak sesuai untuk semua jenis pelabur. Leveraj menimbulkan risiko dan kerugian tambahan. Sebelum anda memutuskan untuk berdagang pertukaran mata wang asing, pertimbangkan dengan teliti objektif pelaburan, tahap pengalaman dan toleransi risiko anda. Anda berkemungkinan kehilangan sebahagian atau semua pelaburan awal anda. Jangan melaburkan wang yang anda tidak mampu untuk kehilangan. Didik diri anda tentang risiko yang berkaitan dengan perdagangan pertukaran asing, dan dapatkan nasihat daripada penasihat bebas kewangan atau cukai jika anda mempunyai sebarang pertanyaan mengenainya. Semua data dan maklumat yang disediakan adalah semata-mata untuk tujuan maklumat, dan bukan bertujuan untuk tujuan perdagangan atau nasihat. Prestasi masa lalu tidak semestinya menunjukkan hasil masa depan.